Login to Your Account

Wait For Overall Satraplatin Survival Data, Panel Advises

By Randall Osborne

Wednesday, July 25, 2007
Shares of GPC Biotech Inc., partner Pharmion Corp., and licensee Spectrum Pharmaceuticals Inc. continued to sink Tuesday as an FDA advisory panel debated the merits of satraplatin for second-line, hormone-refractory prostate cancer, in a closely watched case that had investors nervous because of briefing papers posted last week on the agency's website. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription